Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-31,578
Closed -$23.9K 1137
2023
Q1
$23.9K Buy
31,578
+5,693
+22% +$5.29K ﹤0.01% 938
2022
Q4
$24.9K Buy
25,885
+1,884
+8% +$2.66K ﹤0.01% 897
2022
Q3
$52K Sell
24,001
-133
-0.6% -$459 ﹤0.01% 916
2022
Q2
$84K Buy
24,134
+7,159
+42% +$26.7K ﹤0.01% 924
2022
Q1
$86K Buy
16,975
+5,681
+50% +$28.8K ﹤0.01% 930
2021
Q4
$71K Sell
11,294
-161,476
-93% -$1.1M ﹤0.01% 975
2021
Q3
$1.37M Sell
172,770
-46,829
-21% -$385K 0.08% 349
2021
Q2
$1.65M Buy
219,599
+53,303
+32% +$372K 0.09% 266
2021
Q1
$1.01M Buy
166,296
+102,705
+162% +$790K 0.06% 458
2020
Q4
$363K Sell
63,591
-28,973
-31% -$184K 0.03% 955
2020
Q3
$616K Buy
+92,564
New +$824K 0.02% 1026

Other funds holding VXRT

Winton Group's VXRT Position: Q2 2023 in Review

Winton Group sold out of Vaxart (VXRT) in Q2 2023, closing a stake of 31,578 shares — an estimated $23.9K sold.

Winton Group first reported a position in VXRT in Q3 2020 and held it in 11 quarters. The position peaked at $1.65M in Q2 2021. 111 funds tracked by Wall St. Rank hold VXRT as of Q2 2023.

  • Winton Group reported no remaining Vaxart position as of Q2 2023 after selling out during the quarter.
  • Winton Group sold 31,578 Vaxart shares in Q2 2023, an estimated $23.9K.
  • Winton Group first reported a position in Vaxart in Q3 2020 and held it in 11 quarters.
  • Winton Group's Vaxart position peaked at $1.65M in Q2 2021.
  • 111 funds tracked by Wall St. Rank held Vaxart as of Q2 2023.

Based on Winton Group's 13F filing for Q2 2023, filed 14 Aug 2023.